Ocular comorbidities are common in multiple myeloma: results of a large cross-sectional survey

Abstract Both advancing age and multiple myeloma (MM) therapies such as belantamab mafodotin or dexamethasone can be risk factors for ocular complications. We conducted an international online survey of 508 patients with MM; 3% and 2% reported previous craniofacial radiation therapy or belantamab mafodotin, respectively. Common ocular comorbidities included cataracts (59%), dry eyes requiring eyedrops (37%), and blepharitis or styes (24%). Higher typical dexamethasone doses (≥20 milligrams weekly) were associated with cataracts after adjusting for advancing age and time since diagnosis. Compared to lower-dose dexamethasone (0-19 milligrams weekly), high-dose dexamethasone shifted the incidence curve of predicted cataracts approximately 5.4 years earlier. Although 82% of patients reported periodic eye exams (in line with ophthalmologic recommendations for older adults), only 31% had ever received such guidance from their MM teams. In conclusion, ocular issues are common in MM. Corticosteroid-sparing regimens may warrant attention across the age spectrum to reduce the risk of cataracts.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2026-11-13
DOI
https://doi.org/10.1093/oncolo/oyag458
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ocular comorbidities are common in multiple myeloma: results of a large cross-sectional survey

Jennifer M. Ahlstrom, Rahul Kumar Banerjee, Andrew J. Cowan, Parisa Taravati et al.
The Oncologist
Multiple Myeloma Research and Treatments
article

Ocular comorbidities are common in multiple myeloma: results of a large cross-sectional survey

Jennifer M. Ahlstrom, Rahul Kumar Banerjee, Andrew J. Cowan, Parisa Taravati, Kara I. Cicero, Mason Barnes, Jorge Arturo Hurtado Martínez, Gurbakhash Kaur, Patricia Alejandra Flores Pérez, Jay Hydren
article en

Abstract

Abstract Both advancing age and multiple myeloma (MM) therapies such as belantamab mafodotin or dexamethasone can be risk factors for ocular complications. We conducted an international online survey of 508 patients with MM; 3% and 2% reported previous craniofacial radiation therapy or belantamab mafodotin, respectively. Common ocular comorbidities included cataracts (59%), dry eyes requiring eyedrops (37%), and blepharitis or styes (24%). Higher typical dexamethasone doses (≥20 milligrams weekly) were associated with cataracts after adjusting for advancing age and time since diagnosis. Compared to lower-dose dexamethasone (0-19 milligrams weekly), high-dose dexamethasone shifted the incidence curve of predicted cataracts approximately 5.4 years earlier. Although 82% of patients reported periodic eye exams (in line with ophthalmologic recommendations for older adults), only 31% had ever received such guidance from their MM teams. In conclusion, ocular issues are common in MM. Corticosteroid-sparing regimens may warrant attention across the age spectrum to reduce the risk of cataracts.

The Oncologist
BC Cancer Agency (CA), University of Washington (US), Fred Hutch Cancer Center (US), Icahn School of Medicine at Mount Sinai (US)
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon